Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. (OTC: SMNR) is a late-stage clinical biopharmaceutical company developing non-opioid treatments for acute and chronic pain, with a focus on patients whose needs are not adequately addressed by existing therapies. Its lead candidate, SP-102, is a viscous gel formulation of dexamethasone… From the company’s description.
In fiscal 2025, Semnur Pharmaceuticals, Inc. reported a net loss of $160.42M. Operations used $5.87M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Semnur Pharmaceuticals, Inc. does
In the company’s own words
Semnur Pharmaceuticals, Inc. (OTC: SMNR) is a late-stage clinical biopharmaceutical company developing non-opioid treatments for acute and chronic pain, with a focus on patients whose needs are not adequately addressed by existing therapies. Its lead candidate, SP-102, is a viscous gel formulation of dexamethasone sodium phosphate being developed as an epidural injection for sciatica, also known as lumbosacral radiculopathy; the product is not yet approved. Semnur completed one Phase 3 study and initiated a second Phase 3 trial in 2025, with development aimed at a potential U.S. regulatory submission. The company has no reportable business segments described; its operations center on SP-102, and it plans to evaluate additional non-opioid pain therapies. Semnur was founded in 2013, acquired by Scilex in 2019, and became a public company following its 2025 business combination with Denali Capital Acquisition Corp. It uses Scilex’s commercial and administrative infrastructure under a transition services agreement. As of December 31, 2025, it had 12 contractors and consultants and three Scilex employees dedicated to SP-102.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1913577
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Semnur Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Semnur Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Semnur Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Semnur Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Semnur Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”